Arrowhead Pharma secures $200M milestone from Sarepta Therapeutics
Source: SeekingAlpha
2025-11-24 07:45:50 ET
More on Arrowhead Pharmaceuticals
- Arrowhead Pharmaceuticals, Inc. (ARWR) Discusses FDA Approval and Commercial Launch Plans for REDEMPLO in Familial Chylomicronemia Syndrome Transcript
- Arrowhead Pharmaceuticals, Inc. (ARWR) Discusses FDA Approval and Commercial Launch Plans for REDEMPLO in Familial Chylomicronemia Syndrome - Slideshow
- Arrowhead Is A Buy On REDEMPLO(TM) Approval And Strong Cash Runway
- Arrowhead rises as FDA approves lead drug for rare disorder
- Goldman's 48 potential M&A candidates
Read the full article on Seeking Alpha
For further details see:
Arrowhead Pharma secures $200M milestone from Sarepta Therapeutics
Sarepta Therapeutics Inc.
NASDAQ: SRPT
SRPT Trading
-1.75% G/L:
$16.67 Last:
898,612 Volume:
$17.47 Open:
SRPT Latest News
February 27, 2026 09:00:00 am
Sarepta Therapeutics Announces Call for Applications for the 9th Annual Route 79, The Duchenne Scholarship Program
SRPT Stock Data
$1,921,797,010
96,823,361
N/A
132
N/A
Biotechnology & Life Sciences
Healthcare
US
Cambridge
